Pyxis Oncology In-Licenses Anti-Siglec-15 Monoclonal Antibody From Biosion

Pyxis Oncology Inc PYXS has received an exclusive license to develop and commercialize Biosion Inc's anti-Siglec-15 monoclonal antibody, BSI-060T (now referred to as PYX-106), worldwide, excluding Greater China. 

  • Under the agreement terms, Biosion will receive a $10 million upfront license fee from Pyxis Oncology. 
  • In addition, Biosion has the potential to receive significant milestone payments for PYX-106, totaling up to $222.5 million, and single to low double-digit royalties on commercial sales. 
  • Pyxis Oncology plans to submit the IND for PYX-106 to the FDA by 2H of 2022 and initiate a Phase 1 trial shortly after that. 
  • Under the agreement, Pyxis Oncology has the opportunity to license additional preclinical assets that target anti-Siglec-15 using other treatment approaches.
  • Price Action: PYXS shares are down 1.44% at $4.78 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareContractsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!